Healthy Living

Research Reveals Cystic Fibrosis Severity Is Linked to Fungus

AIT Therapeutics aims to use different approaches than what's available

AIT Therapeutics, a clinical-stage medical device and biopharmaceutical company, is currently using its dedicated expertise in therapeutic approaches to treat lower respiratory tract infections and pulmonary hypertension - conditions that have not been successfully addressed with current standards of care. At present, the company is moving forward with its state-of-the-art nitric oxide generator, which produces the gas from regular air, and its delivery system for the treatment of severe lung infections and bronchiolitis.

On July 12-14th, 2018, AIT Therapeutics presented on the use of inhaled nitric oxide in the treatment of Mycobacterium abscessus lung infections. The company’s findings were presented at the 3rd Annual World Bronchiectasis Conference at Georgetown University, located in Washington D.C. The conference is a pioneering event that gathers together global experts on the most recent research in areas relating to bronchiectasis and nontuberculous mycobacterial lung infections.